Eight children with severe autoimmune diseases who did not respond to conventional therapies were able to completely stop ...
AbbVie Inc. stays a Strong Buy after a Q4 2025 earnings beat led by HUMIRA, plus growth in immunology and neuroscience. Click ...
Hospital for Special Surgery (HSS) today announced the appointment of Anca Dinu Askanase, MD, MPH, as the new Chair of the Department of Medicine and Chief of the Division of Rheumatology, effective ...
AbbVie has submitted applications to the FDA and EMA for new indications for upadacitinib (RINVOQ 15-mg) for the treatment of adult and adolescent patients living with non-segmental vitiligo (NSV), ...
Submissions are supported by data from the Phase 3 Viti-Up clinical studies demonstrating upadacitinib achieved the co-primary endpoints of at least a 50% improvement ...
A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in ...
The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.
Litifilimab, a humanized immunoglobulin G1 monoclonal antibody that targets blood dendritic cell antigen 2, has been granted ...
Feb 3 (Reuters) - AstraZeneca said on Tuesday that the U.S. health regulator had rejected its application for an ...
Subcutaneous anifrolumab is superior to placebo in multiple systemic lupus erythematosus disease activity measures at 52 weeks, according to data published in Arthritis & Rheumatology.“As a ...
Biogen (NASDAQ:BIIB) executives said the company ended 2025 “slightly above the upper end” of its guidance, pointing to ...
Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results